Document And Entity Information
Document Type
Document Type
Document Quarterly Report
Document Transition Report
Document Period End Date
Document Period End Date
Securities Act File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Current Reporting Status
Entity Current Reporting Status
Entity Shell Company
Entity Shell Company
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
CONDENSED CONSOLIDATED BALANCE SHEETS
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
CURRENT ASSETS:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable - related party
Prepaid Expense, Current
Prepaid expenses
Income Taxes Receivable
Tax incentive receivable
Other Assets, Current
Other current assets
Assets, Current
Total Current Assets
Property, Plant and Equipment, Net.
Property, plant and equipment, net
Intangible Assets, Net (Excluding Goodwill)
Intangible assets, net
Restricted Cash, Noncurrent
Restricted cash
Other Assets, Noncurrent
Other assets
Equity Method Investments
Equity method and other investments
Operating Lease, Right-of-Use Asset
Right-of-use assets - operating leases, net
Right-of-use assets
Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Right-of-use assets
Right-of-use assets - finance leases, net
Assets
TOTAL ASSETS
Liabilities and Equity [Abstract]
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Liabilities, Current [Abstract]
CURRENT LIABILITIES:
Accounts Payable, Current
Accounts payable
Accrued Liabilities, Current
Accrued expenses
Accrued expenses
Operating Lease, Liability, Current
Lease obligations - operating leases, current
Finance Lease, Liability, Current
Lease obligations - finance leases, current
Deferred Income, Current
Deferred revenue - related party, current
Notes Payable, Current
Note payable, net, current
Outstanding debt obligation
Other Liabilities, Current
Other current liabilities
Other Liabilities, Current, Total
Liabilities, Current
Total Current Liabilities
Deferred Income, Noncurrent
Deferred revenue - related party
Operating Lease, Liability, Noncurrent
Lease obligations - operating leases
Finance Lease, Liability, Noncurrent
Lease obligations - finance leases
Asset Retirement Obligation
Asset retirement obligations at end of period
Asset retirement obligations at beginning of period
Asset retirement obligations
Notes Payable, Noncurrent
Note payable, net
Liabilities
TOTAL LIABILITIES
Commitments and Contingencies.
COMMITMENTS AND CONTINGENCIES (Note 12)
Equity, Attributable to Parent [Abstract]
SHAREHOLDERS' DEFICIT:
Common Stock, Value, Issued
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 81,446,126 and 81,120,931 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Additional Paid in Capital
Capital in excess of par value
Treasury Stock, Common, Value
Treasury shares
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive gain
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Accumulated deficit
Equity, Attributable to Parent
Ending Equity Balance
Beginning Equity Balance
Total Shareholders' Deficit
Liabilities and Equity
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT
Common Stock, Par or Stated Value Per Share
Common stock, par value
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Shares issued to related party
Common Stock, Shares, Outstanding
Ending Equity Balance (shares)
Beginning Equity Balance (shares)
Common stock, shares outstanding
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Statement [Table]
Statement [Table]
Product and Service [Axis]
Product and Service [Domain]
Revenue from related parties earned for services rendered.
Related Party Service Revenue [Member]
Service revenue - related party
Statement [Line Items]
Statement [Line Items]
Revenues
Total revenue
Operating Expenses [Abstract]
Operating expenses:
Selling and Marketing Expense
Cost of service revenue - related party
General and Administrative Expense
General and administrative
Research and Development Expense
Research and development
Operating Expenses
Total operating expenses
Total operating expenses
Operating Income (Loss)
Loss from operations
Other Nonoperating Income (Expense) [Abstract]
Other non-operating income (expense):
Gain (Loss), Foreign Currency Transaction, before Tax
Foreign currency loss (gain)
Foreign currency (loss) gain
Investment Income, Interest
Interest income
Interest Expense, Operating and Nonoperating
Interest expense
Net loss
Net loss for the period
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Other comprehensive gain (loss):
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Other comprehensive gain (loss)
Foreign currency translation gain (loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Net Income (Loss) Available to Common Stockholders, Basic
Net loss
Earnings Per Share, Basic
Basic net loss per ordinary share
Earnings Per Share, Diluted
Diluted net loss per ordinary share
Weighted Average Number of Shares Outstanding, Basic
Weighted-average number of ordinary shares outstanding, basic
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average number of ordinary shares outstanding, diluted
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' DEFICIT
Equity Components [Axis]
Equity Component [Domain]
Common Stock [Member]
Ordinary Shares
Additional Paid-in Capital [Member]
Capital in Excess of Par Value
Treasury Stock, Common [Member]
Treasury Shares
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Gain (Loss)
Retained Earnings [Member]
Accumulated Deficit
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Share-based compensation activity
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture
Share-based compensation activity (shares)
Stock Issued During Period, Value, New Issues
Issuance of ordinary shares in at-the-market offering
Stock Issued During Period, Shares, New Issues
Shares issued
Issuance of ordinary shares in at-the-market offering (shares)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Issuance costs in connection with ordinary shares
Treasury Stock, Value, Acquired, Cost Method
Repurchase of treasury shares
Treasury Stock, Shares, Acquired
Repurchase of treasury shares (shares)
Stock Issued During Period, Value, Acquisitions
Issuance of ordinary shares in connection with license agreement
Stock Issued During Period, Shares, Acquisitions
Issuance of ordinary shares in connection with license agreement (shares)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Taxes withheld on issuance of share-based awards
Taxes withheld on issuance of share-based awards
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation
Share-based compensation expense
Depreciation, Depletion and Amortization
Depreciation and amortization
Amount of change in right of use assets.
Change In Right Of Use Assets
Change in right-of-use assets
Gain (Loss) on Termination of Lease
Gain on termination of lease liabilities
Gain (Loss) on Disposition of Property Plant Equipment
Loss (gain) on disposal of equipment, furniture and fixtures
Asset Retirement Obligation, Accretion Expense
Amortization of interest on asset retirement obligations
Amortization of Debt Discount (Premium)
Amortization of debt discount
Amount of addition (reduction) to the amount of acquired in-process research and development assets.
Increase Decrease in Acquired In-process Research and Development Assets
Acquired in-process research and development
Increase (Decrease) in Operating Assets [Abstract]
(Increase) decrease in operating assets:
Increase (Decrease) in Accounts Receivable, Related Parties
Accounts receivable - related party
Increase (Decrease) in Contract with Customer, Asset
Contract assets - related party
Increase (Decrease) in Inventories and Other Operating Assets
Inventory
Increase (Decrease) in Prepaid Expense
Prepaid expenses
Increase (Decrease) in Other Receivables
Tax incentive receivable
Increase (Decrease) in Other Current Assets
Other current assets
Increase (Decrease) in Other Noncurrent Assets
Other assets, net
Increase (Decrease) in Operating Liabilities [Abstract]
Increase (decrease) in operating liabilities:
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accrued Liabilities
Accrued expenses
Amount of increase (decrease) in obligation for lease.
Increase (Decrease) in Lease Liabilities
Lease liabilities
Increase (Decrease) in Other Current Liabilities
Other current liabilities
Increase (Decrease) in Deferred Revenue
Deferred revenue - related party
Net Cash Provided by (Used in) Operating Activities
Cash flows from operations
Net cash provided by (used in) operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment
Purchase of property, plant and equipment
Payments to Acquire in Process Research and Development
Acquisition of in-process research and development assets
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Cash flows from financing activities:
Proceeds from Stock Options Exercised
Exercise of share options
Payment, Tax Withholding, Share-Based Payment Arrangement
Payments of withholdings on shares withheld for income taxes
Finance Lease, Principal Payments
Payments on lease obligations - financing leases
Proceeds from Issuance of Common Stock
Proceeds from the issuance of ordinary shares
Aggregate offering price authorized through at-market offerings
Payments of Stock Issuance Costs
Issuance costs in connection with ordinary shares
Offering costs
Payments for Repurchase of Common Stock
Payment for treasury shares
Net Cash Provided by (Used in) Financing Activities
Net cash (used in) provided by financing activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Net increase (decrease) in cash, cash equivalents and restricted cash
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash, cash equivalents and restricted cash at end of the period
Cash, cash equivalents and restricted cash at beginning of the period
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows
Cash, cash equivalents
Noncash Investing and Financing Items [Abstract]
Supplemental disclosure of non-cash transactions:
Asset Acquisition, Consideration Transferred, Contingent Consideration
Fixed asset acquisitions included in accounts payable and accrued expenses
Future contingent consideration
Asset Retirement Obligation, Revision of Estimate
Change in estimate of asset retirement obligation
Change in estimate
Stock Issued
Issuance of shares in connection with acquisition of in-process research and development asset
Receivable related to the sale of fixed assets that is included in the balance of other current assets at period-end.
Non Cash Transaction Receivable From Sale of Fixed Assets Included in Other Current Assets
Receivable from sale of fixed assets included in other current assets
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Organization and Basis of Presentation
Business Description and Basis of Presentation [Text Block]
Organization and Basis of Presentation
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Equity Method and Other Investments
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Equity Method and Other Investments
Accrued Expenses
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accrued Expenses
Other Current Liabilities
Other Liabilities Disclosure [Text Block]
Other Current Liabilities
Share-Based Compensation
Share-Based Payment Arrangement [Text Block]
Share-Based Compensation
Ordinary Shares
Equity [Text Block]
Ordinary Shares
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Related-Party Transactions
Related Party Transactions Disclosure [Text Block]
Related-Party Transactions
Leases
Lessee, Operating Leases [Text Block]
Leases
Debt Financing
Debt Disclosure [Text Block]
Debt Financing
Commitments and Contingencies
Commitments Disclosure [Text Block]
Commitments and Contingencies
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
Consolidation, Policy [Policy Text Block]
Consolidation
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Restricted Cash
Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements
Asset Retirement Obligation [Policy Text Block]
Asset Retirement Obligations
Disclosure of accounting policy for IDA Ireland Grants.
Schedule of Ireland Grants [Policy Text Block]
IDA Ireland Grant
Revenue [Policy Text Block]
Revenue Recognition
Research and Development Expense, Policy [Policy Text Block]
Research and Development
Stockholders' Equity, Policy [Policy Text Block]
Treasury Shares
Earnings Per Share, Policy [Policy Text Block]
Net Loss per Ordinary Share
Segment Reporting, Policy [Policy Text Block]
Segment Information
Disclosure of accounting policy pertaining to new accounting pronouncements adopted.
Recent Accounting Pronouncements Adopted [Policy Text Block]
Recent Accounting Pronouncements Adopted
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements Not Yet Adopted
Restrictions on Cash and Cash Equivalents [Table Text Block]
Schedule of Restricted Cash
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of Financial Assets and Liabilities Measured at Fair Value
Schedule of Change in Asset Retirement Obligation [Table Text Block]
Schedule of Change in Asset Retirement Obligations
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Securities Excluded from Computation of Diluted Net Loss per Share
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Net Loss for the Segment
Long-Lived Assets by Geographic Areas [Table Text Block]
Schedule of Long-lived Assets by Geographical Area
Equity Method Investments [Table Text Block]
Schedule of Equity Method and Other Investments
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
Other Current Liabilities [Table Text Block]
Schedule of Other Current Liabilities
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Restricted Stock Units (RSUs) [Member]
Restricted share units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of Share Option Activity
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Schedule of Restricted Share Unit (RSU) Activity
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Schedule of Share-Based Compensation Expense
Related Party Transaction [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Schedule of Deferred Revenue Recognition
Lease, Cost [Table Text Block]
Schedule of Components of Lease Cost
Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases [Table Text Block]
Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases
Schedule of Components of Leveraged Lease Investments [Table Text Block]
Schedule of Other Information Related to Leases
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
Schedule of Future Minimum Payments Under Non-cancellable Leases [Table Text Block]
Schedule of Future Minimum Payments Under Non-Cancellable Leases
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Maximum [Member]
Maximum
Counterparty Name [Axis]
Counterparty Name [Domain]
Information pertaining to Hologen Limited.
Hologen Limited [Member]
Hologen Limited
Information pertaining to Eli Lilly and Company.
Eli Lilly and Company [Member]
Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement [Member]
Collaboration Agreement
Asset purchase agreement as defined by the Company.
Asset Purchase Agreement [Member]
Asset Purchase Agreement
Collaborative transaction with Hologen Limited.
Hologen Transaction Agreement [Member]
Hologen Strategic Agreement
Information pertaining to the collaborative agreement with Eli Lilly and Company.
Eli Lilly and Company Collaboration Agreement [Member]
Eli Lilly Collaboration Agreement
Ownership [Axis]
Ownership [Domain]
Represents the member information pertaining to Hologen Neuro AI Limited.
Hologen Neuro AI Limited [Member]
Hologen Neuro AI Limited
Represents the member information pertaining to MeiraGTx Manufacturing Limited.
MeiraGTx Manufacturing Limited [Member]
MeiraGTx Manufacturing Limited
Legal Entity [Axis]
All Entities [Member]
Represents the member information pertaining to MeiraGTx Neuro UK Limited.
MeiraGTx Neuro UK Limited [Member]
MeiraGTx Neuro UK Limited
Asset Acquisition [Axis]
Asset Acquisition [Domain]
Represents the member information pertaining to research, development, manufacture and exploitation of Seller's gene therapy product for the treatment of X-linked retinitis pigmentosa related to mutations in the RPGR gene (the "RPGR Product"), and other related assets.
Research, Development And Other Assets [Member]
Research, Development And Other Assets
Sale of Stock [Axis]
Sale of Stock [Domain]
Represents the member information pertaining to public offering.
Public Offering
Public offering.
Lender Name [Axis]
Line of Credit Facility, Lender [Domain]
Information pertaining to the financing agreement with Perceptive Credit Holdings..
Perceptive Credit Holdings
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Secured Debt [Member]
Secured Debt
Related and Nonrelated Parties [Axis]
Related and Nonrelated Parties [Domain]
Pertaining to JJDC - the investment arm of Johnson & Johnson and owner of Janssen.
JJDC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Represents the total number of clinical programs that have reached late-stage development.
Number of Late Stage Clinical Programs
Number of late stage clinical programs
Represents the total number of manufacturing facilities licensed for Good Manufacturing Practice (GMP) production.
Number of GMP-Licensed Manufacturing Facilities
Number of GMP-Licensed
Represents the minimum duration over which the company has developed its proprietary manufacturing platform process.
Minimum Development Period of Proprietary Manufacturing Platform
Minimum development period of proprietary manufacturing platform
Represents the minimum number of different viral vectors developed and tested, demonstrating leading yield, quality, and commercial readiness.
Minimum Number of Distinct Viral Vectors Utilized
Minimum number of distinct viral vectors utilized
Milestone funding received in collaboration with Hologen Limited.
Milestone funding upfront payment received
Milestone funding upfront payment received
Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device
Milestone funding to provide additional capital
Milestone funding to provide additional capital
Stock issued during period in connection with strategic agreement.
Class A shares of Hologen received in transaction
Class A shares of Hologen received in transaction
Additional milestone funding received in collaboration with Hologen Limited.
Additional milestone payment received
Additional funding payment received
Subsidiary, Ownership Percentage, Parent
Minority interest ownership percentage
Subsidiary, Ownership Percentage, Noncontrolling Owner
Percentage of issued share capital
Represents the maximum ownership percentage may hold if option is exercised.
Maximum Ownership Percentage May Hold if Option is Exercised
Maximum ownership percentage
Represents the option exercise period.
Agreement, Option Exercise Period
Agreement, Option exercise period
Funding received from the Company's collaboration agreement with Janssen Pharmaceuticals for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases..
Collaboration Agreement Funding Received
Initial funding
Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage
Ownership interest
Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
Agreement, Sell Or Transfer Of Shares, Notice Period
Number of business days
Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.
Contingent funding available
Milestone funding available in other near-term cash consideration upon the achievement of certain development and regulatory approval milestones.
Milestone funding available upon certain development and regulatory approvals
Milestone funding contingent on development and regulatory approval
Payments to Acquire Productive Assets
Upfront cash payment
The amount of sales threshold required to trigger contingent consideration payment.
Sales Threshold required to Trigger Contingent Consideration Payment
Sales threshold payment
The amount of milestone payment to be received.
Milestone Payment to be Received
Milestone payment to be received
Net Proceeds From Issuance Of Common Stock
Net Proceeds From Issuance Of Common Stock
Net proceeds from issuance of common stock, net
Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.
Asset Purchase Agreement Funding Received
Non-refundable upfront cash funding
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Level 1
Measurement Frequency [Axis]
Measurement Frequency [Domain]
Fair Value, Recurring [Member]
Fair value measurements on recurring basis
Asset Class [Axis]
Asset Class [Domain]
Cash and Cash Equivalents [Member]
Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash and fair value measurements
Fair Value, Net Asset (Liability)
Fair value, net asset (liability)
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Asset retirement obligations
Asset Retirement Obligation, Liabilities Settled
Asset retirement obligation liability
Leasehold Improvements, Gross
Leasehold improvements associated with terminated lease
Asset Retirement Obligation, Cash Paid to Settle
Decontamination costs related to ARO
Amount of gain (loss) on termination of lease before expiration of lease term.
Gain on termination of lease liabilities
Gain on termination of lease
Amortization of interest on asset retirement obligation.
Asset Retirement Obligations, Amortization of Interest
Amortization of interest
Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)
Effects of exchange rate changes
Government Assistance [Table]
Government Assistance, Type [Axis]
Government Assistance, Type [Domain]
Represents information pertaining to IDA Ireland grants for financial assistance.
Grants IDA Ireland [Member]
IDA Ireland Financial Assistance Grants
Represents information pertaining to IDA Ireland grants for employment.
Grants IDA Ireland Employment [Member]
IDA Ireland Employment Grants
Represents information pertaining to IDA Ireland grants for capital expenditures.
Grants IDA Ireland Capital [Member]
IDA Ireland Capital Grants
Minimum [Member]
Minimum
Government Assistance [Line Items]
IDA Ireland grant
Amount of financial assistance available for each new job created.
Grant amount for job creation
Grant funding for each new job created
Amount of financial assistance available for creation of machinery and equipment that provides opportunities for new jobs.
Grant amount for machinery and equipment
Grant funding available for the creation of machinery and equipment that leads to job creation, expressed as a percent of total cost to produce machinery and equipment.
Grants for machinery and equipment as a percentage of total cost to make
Grant amount for machinery and equipment (percent of actual expenditure)
Represents the aggregate number of jobs created in order to be eligible to receive financial assistance under IDA Ireland grants.
Number of new jobs created to receive Grant funding
Aggregate number of new jobs required to receive grant benefits
Financial assistance duration period, measured from the last date of payment received in IDA Ireland grant funding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Financial Assistance Duration From Last Grant Payment
Termination period (from last grant payment)
Financial assistance duration period, measured from the date in which capital investments for eligible machinery and equipment are completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Financial Assistance Duration From Completion of Capital Investment
Termination period (upon completion of capital investment)
Expenditure requirements on eligible machinery and equipment in order to receive maximum benefits from IDA Ireland financial assistance grants.
Expenditure requirement for grant funding on eligible machinery and equipment
Expenditure requirement on eligible machinery and equipment
Period benchmark in which the Company may be held to repay a portion of capital grants if a job for which the Company received employment grant funding remains vacant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Period of job vacancy before grant funding becomes repayable
Vacant job duration prompting repayment of grant funding
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Warrant [Member]
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss per ordinary share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Anti-dilutive securities excluded from EPS
Number of Reportable Segments
Number of reportable segments
Number of Operating Segments
Number of operating segments
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Service revenue from related parties
Service revenue - related party
The segment total of research and development expenses.
Segment general and administrative expenses
General and administrative
Amount of expense for clinical trials for AAV-hAQP1 drug substances.
Clinical Programs Drug Product 2
AAV-hAQP1
Amount of expense for clinical trials for AAV-GAD drug substances.
Clinical Programs Drug Product 4
AAV-GAD
Amount of expense for research and development pertaining to clinical trials for drug substances.
Research and development clinical trials
Other ocular diseases
Amount of expense for research and development pertaining to manufacturing of drug substances.
Research and development Manufacturing
Manufacturing
Amount of expense for pre-clinical research relating to gene regulation.
Pre-clinical research Gene Regulation
Gene regulation
Amount of expense for pre-clinical research relating to neurodegenerative diseases.
Pre-clinical research Neurodegenerative Diseases
Neurodegenerative diseases
Amount of expense for pre-clinical research relating to preclinical ocular diseases.
Pre-clinical research Preclinical Ocular Diseases
Preclinical ocular diseases
Amount of expense for research and development classified as other.
Research and development other
Other research and development
Other segment items of income (expense).
Other segment items income statement
Other segment items
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Segment net income (loss)
Segment net loss
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Geographical [Axis]
Geographical [Domain]
UNITED STATES
United States
UNITED KINGDOM
United Kingdom
European Union [Member]
European Union
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets by geographical area
Long-Lived Assets
Non-current assets
Equity Method Investment [Table]
Investment, Name [Axis]
Investment, Name [Domain]
Represents information pertaining to Visiogene LLC.
Visiogene LLC
Represents information pertaining to equity method investments other than Visogene LLC.
Other Investments
Schedule of Equity Method Investments [Line Items]
Equity Method and Other Investments
Equity Method Investment, Ownership Percentage
Equity ownership in outstanding ordinary shares
Ownership percentage
Equity Method Investment, Quoted Market Value
Carrying Value
Equity Method Investment, Aggregate Cost
Cost Basis
Accrued Liabilities Accrued Compensation And Benefits
Accrued Liabilities Accrued Compensation And Benefits
Compensation and benefits
Accrued Professional Fees, Current
Professional fees
Accrued Research And Development
Accrued Research And Development
Research and development
Deposit Liabilities, Accrued Interest
Interest on Tranche 1 Notes
Accrued Liabilities Accrued Manufacturing Costs Expense.
Accrued Liabilities Accrued Manufacturing Costs Expense
Manufacturing costs
Accrued Clinical Trial Costs
Accrued Clinical Trial Costs
Clinical trial costs
Other Accrued Liabilities, Current
Other
Amount of upfront payment liabilities, due within one year or the normal operating cycle, if longer.
Upfront Payment Liabilities, Current
Hologen Limited Upfront Payments
Other Sundry Liabilities, Current
Other
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Number of Options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Number of options, Ending balance
Number of options, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Number of options, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Number of options, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Number of options, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Number of options, Expired
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, Ending balance
Weighted-average exercise price, Beginning balance
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-average exercise price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted-average exercise price, Forfeited
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Weighted-average exercise price, Expired
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Options additional disclosures
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Number of options, Options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-average exercise price, Options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life of options, outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life of options, exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Number of options, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate intrinsic value, options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate intrinsic value, options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted share units
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of restricted share units, Ending balance
Number of restricted share units, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Number of restricted share units, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Ending balance
Weighted-average grant date fair value, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Vested
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Domain]
Research and Development Expense [Member]
Research and Development Expenses
General and Administrative Expense [Member]
General and Administrative Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense
Total share-based compensation
Vesting [Axis]
Vesting [Domain]
First Anniversary [Member]
First Anniversary [Member]
First Anniversary
Second Anniversary member
Second Anniversary [Member]
Second Anniversary
Third anniversary member
Third Anniversary [Member]
Third Anniversary
Fourth Anniversary member
Fourth Anniversary [Member]
Fourth Anniversary
Over Three Years Member
Over Three Years [Member]
Over Three Years
Grantee Status [Axis]
Grantee Status [Domain]
Director [Member]
Directors
Plan Name [Axis]
Plan Name [Domain]
Information pertaining to the Company's 2018 equity incentive award plan.
2018 Incentive Award Plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Vesting percentage
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value
Fair value of options, Vested
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Total unvested options compensation expense not yet recognized
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Period expected to realize unrecognized compensation expense
The number of shares that have fully vested and have been deferred.
Vested shares deferred
Shares vested and deferred
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Ordinary shares withheld for statutory tax requirements
Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Excess Tax Benefit from Share-based Compensation, Operating Activities1
Excess tax benefits in cash flows from operations
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Excess Tax Benefit from Share-based Compensation, Financing Activities1
Excess tax benefits in cash flows from financing activities
Share Price
Common stock share price
Stock, Class of Stock [Table]
Information pertaining to BofA Securities, Inc.
Bank of America Securities, Inc. [Member]
B of A Securities, Inc.
Information pertaining to the at-the-market sales agreement to sell shares of the Company's common stock.
Sales Agreement [Member]
At-The-Market Sales Agreement
It represents the information pertaining to the ATM offering.
At-the-market Offering
Public Offering
Share Repurchase Program [Axis]
Share Repurchase Program [Domain]
Represents the information pertaining to share repurchases agreement with Perceptive Life Sciences Master Fund, Ltd.
Share Repurchase Agreement with Perceptive Life Sciences Master Fund, Ltd [Member]
Perceptive Life Sciences Master Fund, Ltd.
Class of Stock [Line Items]
Sale of Stock, Consideration Received Per Transaction
Gross proceeds from sale of ordinary shares
Sale of Stock, Number of Shares Issued in Transaction
Ordinary shares issued in transaction
Share Repurchase Program, Authorized, Number of Shares
Number of shares repurchased
Share Repurchase Program, Authorized, Amount
Aggregate purchase price
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Income Tax Expense (Benefit)
Provision recorded for income tax expense (benefit)
Janssen Pharmaceuticals Inc [Member]
Janssen Pharmaceuticals Inc
Credit Facility [Axis]
Credit Facility [Domain]
Term loans granted under the Company's financing agreement.
Term Loan
Shares Issued, Price Per Share
Purchase price per share
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
Deferred revenue recognized during period
Deferred revenue recognized as service revenue during the period
Deferred revenue recognized as service revenue during the period
Portion of the principal amount, agreed to redeem.
Debt Instrument, Principal Amount, Amount to Redeem
Portion of the principal amount, agreed to redeem
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrant exercise price
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
Revenue, unsatisfied performance obligation, amount
Deferred revenue, unsatisfied performance obligations
Information pertaining to Perceptive Advisors, LLC.
Perceptive Advisors, LLC
Information pertaining to the financing agreement with Perceptive Advisors, LLC.
Secured Financing Agreement
Notes Purchase Agreement
Contract with Customer, Liability
Deferred revenue at period-end
The amount of milestone payments collected or invoiced, categorized as other.
Contract with Customer, Liability, Other Amounts Collected or Invoiced
Other amounts collected or invoiced
Finance Lease, Right-of-Use Asset, Amortization
Amortization of right-of-use assets
Finance Lease, Interest Expense
Interest on lease liabilities
Variable Lease, Cost
Total finance lease cost
Operating Lease, Cost
Operating lease cost
Short-Term Lease, Cost
Short-term lease cost
Lease, Cost
Total lease cost
Operating Lease [Abstract]
Operating Lease [Abstract]
Operating leases
Operating Lease, Liability
Capitalized lease obligations
Operating lease liability
Finance Lease [Abstract]
Finance Lease [Abstract]
Finance leases
Finance Lease, Liability
Capitalized lease obligations
Finance lease liability
Weighted Average Remaining Lease Term [Abstract]
Weighted Average Remaining Lease Term [Abstract]
Weighted-average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Operating leases
Finance Lease, Weighted Average Remaining Lease Term
Finance leases
Weighted Average Discount Rate [Abstract]
Weighted Average Discount Rate [Abstract]
Weighted-average discount rate
Operating Lease, Weighted Average Discount Rate, Percent
Operating leases
Finance Lease, Weighted Average Discount Rate, Percent
Finance leases
Cash paid for amounts included in measurement of lease liabilities [Abstract]
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Cash paid for amounts included in the measurement of lease liabilities
Operating Lease, Payments
Operating cash flows from operating leases
Amount of cash outflow from finance lease.
Finance Lease Payments
Financing cash flows from finance leases
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2026
Lessee, Operating Lease, Liability, to be Paid, Year One
2027
Lessee, Operating Lease, Liability, to be Paid, Year Two
2028
Lessee, Operating Lease, Liability, to be Paid, Year Three
2029
Lessee, Operating Lease, Liability, to be Paid, Year Four
2030
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Thereafter
Lessee, Operating Lease, Liability, to be Paid
Total undiscounted lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
2026
Finance Lease, Liability, to be Paid, Year One
2027
Finance Lease, Liability, to be Paid, Year Two
2028
Finance Lease, Liability, to be Paid, Year Three
2029
Finance Lease, Liability, to be Paid
Total undiscounted lease payments
Finance Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Lease Maturity Term
Lease Maturity Term
Lease term
Operating Lease, Expense
Operating lease rent expenses
The number new leases recognized during the period.
Operating Lease Number New Leases Recognized
New leases recognized during period
Line of Credit Facility [Table]
Scenario [Axis]
Scenario [Domain]
Information related to warrants to buy common shares with various exercise prices.
Exercise Price - Scenario I
Information related to warrants to buy common shares with various exercise prices.
Exercise Price - Scenario II
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount
Initial face amount
Debt Instrument, Interest Rate, Stated Percentage
Stated interest rate
Period of time between changes in the offered SOFR rate, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Secured Overnight Financing Rate, Adjustment Term
SOFR adjustment term
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]
Floor percentage for basis points added to the reference rate to compute the variable rate on the debt instrument.
Basis Spread on Variable Rate Floor
Floor percentage
Long-Term Debt, Weighted Average Interest Rate, at Point in Time
Interest rate at period-end
Secured Debt, Current
Term loan outstanding amount
Debt Instrument, Increase, Accrued Interest
Increase in accrued interest
Interest Expense, Debt
Interest expense on debt
Guaranteed Benefit Liability, Net
Obligations secured by UK and Ireland subsidiaries
Liquidity requirement for minimum amount of cash and bank accounts to be maintained and secured under the financing agreement with Perceptive Credit Holdings.
Cash liquidity requirement
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Shares available through warrants
Common Stock, Discount on Shares
Debt discount, allocated fair value of warrants
Debt Issuance Costs, Net
Debt discount, capitalized issuance costs
Debt Instrument, Unamortized Discount
Unamortized debt discount
Loss Contingency, Damages Sought, Value
Total potential benefit associated with the filed claims
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Rule 10b5-1 Arrangement Modified [Flag]
Rule 10b5-1 Arrangement Modified [Flag]
Rule 10b5-1 Arrangement Modified
Non Rule 10b5-1 Arrangement Modified [Flag]
Non Rule 10b5-1 Arrangement Modified [Flag]
Non-Rule 10b5-1 Arrangement Modified